ArticleDiabetes spectrum : a publication of the American Diabetes Association2025
Observations of Glucagon-Prescribing Patterns for High-Risk People With Diabetes Within a Federally Qualified Health Center.
Article in Diabetes spectrum : a publication of the American Diabetes Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHypoglycemia is a serious complication in people with diabetes. Risk factors include increased age, certain comorbidities, and certain glucose-lowering medications. Although the American Diabetes Association recommends prescribing glucagon to individuals at high risk for hypoglycemia for use in emergent episodes, glucagon use remains low. This is particularly concerning in federally qualified health centers (FQHCs), where patients face socioeconomic barriers that may exacerbate this gap in care. This study evaluated glucagon-prescribing rates among high-risk patients with diabetes in a FQHC. RESEARCH DESIGN AND
methodsA retrospective chart review was conducted of patients with diabetes seen between March 2022 and March 2023 who were prescribed a high-risk medication and/or had a history of hypoglycemia. Demographics and clinical characteristics such as history of hypoglycemia, high-risk medications, and active glucagon prescriptions were analyzed using descriptive statistics and comparative tests to determine characteristics associated with glucagon prescriptions.
resultsOf the 7,304 patients, 95% had type 2 diabetes, and 61.5% were prescribed insulin, but only 4.4% had an active glucagon prescription. Among 65 individuals with documented hypoglycemia, 80% were prescribed a high-risk medication, yet only 13.8% were prescribed glucagon. Patients with type 1 diabetes were more likely to have glucagon prescribed (
conclusionGlucagon was significantly under-prescribed in this high-risk population, highlighting gaps in applying clinical guidelines to practice as well as gaps in access to preventive care. These findings will inform provider education and interventions to improve glucagon-prescribing practices.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.